Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Capital Reconstruction

23rd Jul 2007 09:39

Advanced Medical Solutions Grp PLC23 July 2007 For immediate release 23 July 2007 Advanced Medical Solutions Group plc ("AMS" or "the Company") Capital Reconstruction Reduction of the Company's share capital by the cancellation of its Deferred Shares of 5p each and the cancellation of the Company's share premium account Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the globalmedical technology company today announces further progress in its CapitalReconstruction that will enable it to pay a dividend in the future should theBoard make a recommendation to do so. Further to the announcement of 6 June 2007, the Company announces that the HighCourt of Justice confirmed the reduction of the Company's share capital by thecancellation of its Deferred Shares of 5p each and the cancellation of theCompany's share premium account on 4 July 2007. The reduction and cancellationbecame effective on 6 July 2007 on the registration by the Registrar ofCompanies of the court order and of the minute approved by the court setting outthe particulars of the Company's share capital as altered by that order bycertificate given by the Registrar on 16 July 2007. -- ENDS -- For further information, please contact: Advanced Medical Solutions Group plc +44 (0) 01606 545508Don Evans (Chief Executive Officer)Mary Tavener (Group Finance Director)www.admedsol.com Buchanan Communications +44 (0) 020 7466 5000Mark Court/Mary-Jane Johnson Notes to Editors: Advanced Medical Solutions is a UK based company developing and providingleading edge technology to the $15 billion global woundcare market. Founded in 1991 and quoted on AIM, the Company is focused on the design,development, manufacture and sale of advanced woundcare dressings and productsfor closing wounds and sealing tissue. AMS provides a full range of advanced woundcare products for sale in hospital,nursing home and community care markets. The main indications are for chronicwounds such as ulcers and pressure sores. These products pioneer the concept ofmoist wound healing to allow wounds to heal faster and with less pain andscarring if they remain moist. They protect the wound, deal with tissue fluidsand provide an optimal environment for healing to occur. AMS' resources ensurea unique position as a vertically integrated 'one stop shop' to provide allcategories of moist wound healing products. The Company has the capability tomove a product from design and development through to production and deliveryready for distribution into customer markets. The acquisition of MedLogic in 2002 has brought AMS products based uponcyanoacrylate adhesive technology which allow the closure of wounds followingtrauma or surgical incisions, or seal skin to protect against breakdown or woundinfection. These products address the emerging tissue adhesives and sealantssegment of the wound closure market. AMS' technology and products currently serve the majority of the key globalmarkets and strategic partners. This information is provided by RNS The company news service from the London Stock Exchange

Related Shares:

Advanced Medical Solutions Group
FTSE 100 Latest
Value8,407.44
Change4.26